D 75N95024Q00564_CSS_Amendment 1.pdf

COMBINED SYNOPSIS / SOLICITATION

75N95024Q00564

TITLE: Portfolio Impact Analysis for the Therapeutic Development Branch (TDB), NCATS

Amendment 1 (9/11/2024): Questions and Responses are added as an attachment to this solicitation.

(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice.

This announcement constitutes the only solicitation; quotations are being requested and a written solicitation will not be issued.

(ii) The solicitation number is 75N95024Q00564 and the solicitation is issued as a request for quotation (RFQ). This acquisition is for a commercial item and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13 - Simplified Acquisition Procedures and FAR Part 12 - Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold.

(iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2024-06 effective August 29, 2024.

(iv) The associated NAICS code is 541611 and the Small Business size standard is $24.5M. This requirement is set aside exclusively for Women-Owned Small Business (WOSB).

DESCRIPTION

(v) The Therapeutic Development Branch (TDB) in the intramural Division of Preclinical Innovation (DPI) at the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health (NIH) was established to enable preclinical development through collaborative partnerships. In alignment with accomplishing the Center’s mission, the Branch needs to conduct a portfolio impact analysis, from its inception in 2010 to present. The goal is to capture key metrics and evaluate the program’s research outcomes, including analyzing the economic and other quantitative and qualitative impact measures on further research and development and healthcare. TDB requires the expertise of a firm capable of conducting such types of specialized impact analyses of novel therapeutics and related technologies. The results of this analysis will be used by Branch leadership to inform future research policy and priorities.

See the attached Statement of Work for complete information.

(vi) Period of Performance: The period of performance is nine months, anticipated to be September 24, 2024 – June 24, 2025.

CSS 75N95024Q00564

EVALUATION AND AWARD

(vii) The anticipated award date is September 23, 2024.

(viii) The Government plans to make one firm, fixed-price award resulting from this solicitation. The resulting award will be made to the responsible quoter whose quote conforming to the solicitation will be most advantageous to the Government, price and other factors considered, using comparative evaluations. The following factors shall be used to evaluate quotes:

1. Technical Approach: The feasibility, appropriateness, thoroughness, and creativity of the approach to the Statement of Work.

2. Key Personnel: The sufficiency of education in relevant fields, and the extent of experience designing and conducting economics and economic impact studies in similar or related fields.

3. Past Performance. The Government may use any source of available past performance information (see FAR 13.106-2(b)(3)).

4. Price.

SUBMISSION INSTRUCTIONS

(ix) All responses to this RFQ must be received by 2:00pm Eastern Time on Monday, September 16, 2024 and must reference the solicitation number cited above. Responses must be submitted via email to Kimberly Espinosa at kimberly.espinosa@nih.gov.

(x) This is an RFQ. This request does not commit the Government to pay any costs incurred in the preparation of the submission of this quotation or to contract for supplies or service.

Supplies are of domestic origin unless otherwise indicated by quoter. Any representations and/or certifications attached to this RFQ must be completed by the quoter.

(xi) Responses to this RFQ must include clear and convincing evidence of the quoter’s capability of fulfilling the requirement as it relates to the technical evaluation criteria. Responses may exceed capability or performance characteristics of the solicitation's requirements. The Government reserves the right, but is not required, to award to a response that exceeds capability or performance characteristics of the solicitation's requirements if it provides a benefit to the Government.

(xii) Responses must include the Unique Entity Identifier (UEI), the Taxpayer Identification Number

(TIN), and the certification of business size. Responses must also include a completed copy of the FAR Provision 52.212-3, Offeror Representations and Certifications—Commercial Products and Commercial Services (Nov 2023), with its quote. If the respondent has completed FAR clause 52.212-3 at www.sam.gov, then the respondent does not need to provide a completed copy with its quote.

CSS 75N95024Q00564

mailto:kimberly.espinosa@nih.gov file://nidawfsprd01.nida.nih.gov/SHARED/OM/CMB/RED/NINDS_Section/Contracts/1_Awarded/75N95024P00095_ThorLabs,%20Inc/1_Neg_Acq_Presol-Award/D-Solicitation/www.sam.gov

(xiii) Responses must also include a quotation in U.S. dollars that includes:

1. The total price,

2. Individual prices for each service, if individual services are involved,

3. Prompt payment discount terms,

4. Product or catalog number(s),

5. Description of product/service,

6. Any other information or factors that may be considered in the award decision. Such factors may include: special features required for effective program performance; trade-in considerations; warranty considerations; maintenance availability; and environmental and energy efficiency considerations.

(xiv) For information about this RFQ, contact Kimberly Espinosa, Contracting Officer, at 301-827-

3546 or kimberly.espinosa@nih.gov.

(xv) All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency.

TERMS AND CONDITIONS, PROVISIONS, AND REPRESENTATIONS

(xvi) The provision at FAR 52.252-1, Solicitation Provisions Incorporated by Reference (Feb

1998). This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a solicitation provision may be accessed electronically at www.acquisition.gov.

The following provisions apply to this acquisition and are incorporated by reference:

1. FAR Provision 52.204-7, System for Award Management (Oct 2018)

2. FAR Provision 52.204-16, Commercial and Government Entity Code Reporting (Aug 2020)

3. FAR Provision 52.212-3, Offeror Representations and Certifications—Commercial Products and Commercial Services (May 2024)

(xvii) The clause at FAR 52.252-2, Clauses Incorporated by Reference (Feb 1998). This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at www.acquisition.gov.

In addition to the clauses checked in FAR 52.212-5 (attached), the following clauses also apply to this acquisition and are incorporated by reference:

1. FAR Clause 52.204-13, System for Award Management Maintenance (Oct 2018)

2. FAR Clause 52.204-18, Commercial and Government Entity Code Maintenance (Aug 2020)

3. FAR Clause 52.212-4, Contract Terms and Conditions – Commercial Products and

Commercial Services (Nov 2023)

4. FAR Clause 52.227-14, Rights in Data-General. Under 52.227-14(c)(1), the contractor must obtain approval from the contracting officer to assert copyright in any data first produced in performance of this contract and published in academic, technical or professional journals, symposia proceedings, or similar works. Under 52.227-14(d)(2), the contractor must obtain approval from the contracting officer to use, release to others, reproduce, distribute, or publish any data first produced or specifically used by the contractor in the performance of this contract.

5. HHSAR Clause 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (December 18, 2015)

6. HHSAR Clause 352.224-71 Confidential Information (December 18, 2015). Under Paragraph (2)(i), the following types of information are restricted under this contract: all data and information provided to the Contractor by the Government, and all data and information collected by the Contractor on behalf of the Government. Under Paragraph (2)(ii), the reason(s) for restricting the types of information identified in subparagraph (i) is: the work under this contract requires the Contractor to obtain personal feedback from collaborators and key partners. Honest and unbiased feedback is required for this work to be successful and collaborators and key partners must have assurance that their feedback will not be disclosed outside of the Contractor and the Government.

(xviii) The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement.

ATTACHMENTS

(xix) The following terms, provisions, and clauses are incorporated and attached in full text:

1. Statement of Work

2. FAR Provision 52.212-1, Instructions to Offerors – Commercial Products and Commercial

Services (Sep 2023) (Tailored)

3. FAR Clause 52.212-5, Contract Terms and Conditions Required to Implement Statutes or

Executive Orders–Commercial Products and Commercial Services (May 2024)

4. NIH Electronic Invoice Submission Instructions with IPP (March 21, 2023)

5. Questions and Responses